Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Medical Oncology
•
Her2+
How do you approach HER2 directed therapy with discrepant results between FISH and Oncotype?
Especially if HER2 negative on pathological specimen
Answer from: Radiation Oncologist at Community Practice
At our institution, we don’t do Oncotype for HER2+ (by IHC or FISH) cases. See our published data showing the discrepancy.
Comments
Medical Oncologist at Stanford University, School of Medicine
Thank you so much for sharing this data!
Medical Oncologist at Joliet Oncology - Hematology Associates, Ltd.
What do you do if FISH is negative but oncotype is...
Radiation Oncologist at Varian Medical Systems/Allegheny health network
This is a very rare event and we have not changed ...
3153
3158
3159
Sign in or Register to read more
7878
Related Questions
Would you consider using tucatinib in a patient with de-novo metastatic HER2+ HR(-) breast cancer patient with extensive intraparenchymal and leptomeningeal carcinomatosis?
How do you manage steroid refractory pneumonitis due to docetaxel or trastuzumab?
In a patient with ER+/HER2+ breast cancer with significant residual disease post neoadjuvant TCHP, is there a role of using CDK4/6i in the adjuvant setting with T-DM1?
Would you offer systemic therapy (TH) to a patient with HER2+ (3+), HR- high grade microinvasive breast cancer with single focus or multifocal?
For Her2+ Stage I T1cN0 patients where neoadjuvant therapy is desired to select out patients for post-operative TDM1, is it reasonable to de-escalate neoadjuvant therapy to THP as opposed to TCHP?
What factors do you use to decide between trastuzumab-deruxtecan and sacituzumab govitecan in HER2-low metastatic breast cancer?
Would you consider anthracycline based neoadjuvant therapy for ER negative, HER2 positive inflammatory breast cancer in a premenopausal female given the subset not adequately represented in non-anthracycline regimen trials?
Would you give adjuvant endocrine therapy to a premenopausal woman with early stage node positive breast cancer that was ER negative, PR positive (60%) and HER2 positive?
How would you treat a patient with T1c HR-, HER2+ breast cancer, stage IV, with involvement of multiple bilateral axillary nodes and no evidence of distant metastasis?
Would you treat a patient with cT2 ER+/HER2+ breast cancer with neoadjuvant HER2 directed therapy if HER2 positivity is group 3?
Thank you so much for sharing this data!
What do you do if FISH is negative but oncotype is...
This is a very rare event and we have not changed ...